← Eichor
Study identifier: NCT06282445 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer

Condition: Colorectal Cancer Metastatic  ·  Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine

PhasePhase 2
Planned participants36
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

To evaluate the efficacy and safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Dezhi Li, MD&PhD  ·  15268685138  ·  mdlidezhi@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

The Fourth Affiliated Hospital Zhejiang University School of MedicineJinhua, Zhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06282445